Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor

Abstract Recently, trans-radial intervention has gained popularity as a common procedure to reduce hemorrhagic complications. However, the cuff-type hemostatic device (TR Band) previously used at our institution required 6 h to achieve hemostasis. Since July 2016, we have been using the VasoSTAT, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hirokazu Naganawa, Akira Ito, Shinrou Saiki, Daisuke Nishi, Shinichi Takamatsu, Yoshihisa Ito, Takeshi Suzuki
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/31aa6269a32541168313e9171fdceddb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31aa6269a32541168313e9171fdceddb
record_format	dspace
spelling	oai:doaj.org-article:31aa6269a32541168313e9171fdceddb2021-11-08T10:50:19ZEfficacy of the hemostatic device VasoSTAT and the study of hemostatic factor10.1038/s41598-021-00892-52045-2322https://doaj.org/article/31aa6269a32541168313e9171fdceddb2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00892-5https://doaj.org/toc/2045-2322Abstract Recently, trans-radial intervention has gained popularity as a common procedure to reduce hemorrhagic complications. However, the cuff-type hemostatic device (TR Band) previously used at our institution required 6 h to achieve hemostasis. Since July 2016, we have been using the VasoSTAT, a new hemostatic device that could achieve hemostasis in 4 h. In a verification study, we found that prolonged activated clotting time (ACT) was related to transient hemorrhage occurrence after the hemostatic procedure. Therefore, we designed a hemostatic protocol based on ACT and evaluated its efficacy. In this retrospective and observational study, 78 and 111 patients used the VasoSTAT and TR Band, respectively, from July 2015 to May 2017. In the VasoSTAT group, the ACTs were significantly lower in the hemostasis success (246 ± 46 s) than in the failure group patients (327 ± 59 s) (P < 0.01). Therefore, we applied the hemostatic protocol to 271 patients from May 2017 to March 2020. The hemostasis success rate was 96% in the post-protocol applied group patients, which was significantly higher than the 82% success rate in the pre-protocol applied group patients (P < 0.01). VasoSTAT resulted in adequate hemostasis in 4 h. Further, ACT was predictive of adequate hemostasis.Hirokazu NaganawaAkira ItoShinrou SaikiDaisuke NishiShinichi TakamatsuYoshihisa ItoTakeshi SuzukiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hirokazu Naganawa Akira Ito Shinrou Saiki Daisuke Nishi Shinichi Takamatsu Yoshihisa Ito Takeshi Suzuki Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
description	Abstract Recently, trans-radial intervention has gained popularity as a common procedure to reduce hemorrhagic complications. However, the cuff-type hemostatic device (TR Band) previously used at our institution required 6 h to achieve hemostasis. Since July 2016, we have been using the VasoSTAT, a new hemostatic device that could achieve hemostasis in 4 h. In a verification study, we found that prolonged activated clotting time (ACT) was related to transient hemorrhage occurrence after the hemostatic procedure. Therefore, we designed a hemostatic protocol based on ACT and evaluated its efficacy. In this retrospective and observational study, 78 and 111 patients used the VasoSTAT and TR Band, respectively, from July 2015 to May 2017. In the VasoSTAT group, the ACTs were significantly lower in the hemostasis success (246 ± 46 s) than in the failure group patients (327 ± 59 s) (P < 0.01). Therefore, we applied the hemostatic protocol to 271 patients from May 2017 to March 2020. The hemostasis success rate was 96% in the post-protocol applied group patients, which was significantly higher than the 82% success rate in the pre-protocol applied group patients (P < 0.01). VasoSTAT resulted in adequate hemostasis in 4 h. Further, ACT was predictive of adequate hemostasis.
format	article
author	Hirokazu Naganawa Akira Ito Shinrou Saiki Daisuke Nishi Shinichi Takamatsu Yoshihisa Ito Takeshi Suzuki
author_facet	Hirokazu Naganawa Akira Ito Shinrou Saiki Daisuke Nishi Shinichi Takamatsu Yoshihisa Ito Takeshi Suzuki
author_sort	Hirokazu Naganawa
title	Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
title_short	Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
title_full	Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
title_fullStr	Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
title_full_unstemmed	Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
title_sort	efficacy of the hemostatic device vasostat and the study of hemostatic factor
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/31aa6269a32541168313e9171fdceddb
work_keys_str_mv	AT hirokazunaganawa efficacyofthehemostaticdevicevasostatandthestudyofhemostaticfactor AT akiraito efficacyofthehemostaticdevicevasostatandthestudyofhemostaticfactor AT shinrousaiki efficacyofthehemostaticdevicevasostatandthestudyofhemostaticfactor AT daisukenishi efficacyofthehemostaticdevicevasostatandthestudyofhemostaticfactor AT shinichitakamatsu efficacyofthehemostaticdevicevasostatandthestudyofhemostaticfactor AT yoshihisaito efficacyofthehemostaticdevicevasostatandthestudyofhemostaticfactor AT takeshisuzuki efficacyofthehemostaticdevicevasostatandthestudyofhemostaticfactor
_version_	1718442606067712000

Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor

Ejemplares similares